Category Archives: News

Laboratory Medicine: The Times They Are A Changin’ – Hear more from Dr. Regan at Pathology Horizons

We are looking forward to welcoming  Dr. Irene Regan, Vice President of the Academy of Clinical Scientists and Laboratory Medicine (ACSLM) in Ireland to Pathology Horizons this September.

Dr. Regan will be giving a presentation, entitled “Laboratory Medicine:  The Times They Are a Changin”, which will focus on the key challenges and opportunities of laboratory medicine and address pertinent issues of the day. The 3 I’s concept will be examined; investing in individuals, investing in ideas and investing in infrastructure in order to deliver a modern and up to date laboratory medicine ecosystem of excellence.

A vision for the future will be presented in relation to re-structuring of laboratory based disciplines taking into account the key challenges that face us today and in the future including; laboratory infrastructure, technology trends, global harmonisation of IVDs, health informatics, e-health, connected health, precision medicine, lab in the home and international competition in healthcare. This vision will be presented keeping in mind the need to ensure high quality and reliability of services.

About Pathology Horizons

Pathology Horizons is taking place from 13-15 September 2018 at the Lough Erne Resort in N.Ireland. It is a unique CPD conference, organised by Cirdan that looks at what lies ahead in pathology. Delegates will learn about new technologies, lines of research and procedural developments that are driving the future of pathology. View Agenda

Please note that this conference is open to anyone interested in the area of pathology, however spaces are limited so booking as early as possible  is advisable. Register here

Genome Sequencing as a Diagnostic Aid

There is wide acceptance of the concept of genotype-phenotype correlation in cancers. This concept has been extensively explored in breast carcinogenesis. Early work identified a strong phenotypic signature of breast cancer, which arose in patients with germline BRCA1 mutation. Subsequent data identified four broad intrinsic subtypes of breast cancer, with one being a group of “basal-like” breast cancers, referring to their over-expression of basal cytokeratin markers. Over time, and with transition of intrinsic subtyping to the clinic, the concept of triple-negative breast cancers (i.e., not expressing ER, PR or HER2 by IHC or ISH) evolved as a phenotypic surrogate for “”basal-like” breast cancers. This surrogate was acceptable, given that therapeutic targets available in breast cancer were limited to those directed at the ER/PR pathway and HER2, neither of which were expressed in basal-like breast cancers.

The genomes of several cohorts of triple negative breast cancer have since been analysed. It is clear that they are a heterogeneous group of cancers at the molecular level, with general agreement that some remain true to the basal-like genotype, whilst others have a predominant “immune-activated” or a “mesenchymal” genomic footprint. Still others are nominated “luminal androgen receptor” and are non-basal-like in their molecular profile.

Concomitantly, there has been evolving interest in targeted therapies for TNBC, including targets for basal-like and luminal androgen receptor breast cancers. However, there has been little application of this refined molecular stratification of TNBC in the clinic, possibly due to inaccessibility of genomic analysis for the majority of breast cancers and the fact that the morphological correlates of these TNBC remain under-explored. New technologies, including digital imaging of histology phenotypes, can potentially be recruited to help determine phenotypic subgroups of TNBC relevant to their genotype and therefore their potential targeted therapies. It is possible that these digitally-discovered phenotypes can be applied to stratify TNBC in the routine clinical setting.

Prof. Jane Armes, Clinical Director at NSW Health Pathology in Australia will be discussing further at Pathology Horizons 2018.

About Pathology Horizons

Pathology Horizons is an annual CPD conference that focuses on what lies ahead in pathology. This unique event allows delegates to learn about new technologies, procedural developments and lines of research that are driving the future of Pathology. Unlike other larger pathology conferences, it is a boutique event with only one conference stream. This enables delegates to interact and network with each other as well as with the expert international panel of expert speakers.

Date: 13-15 September 2018

Venue: Lough Erne Resort, N.Ireland

View full agenda
Early Bird ends 31/5/18 – View details on how to register

Dr. Bankhead to speak on how novel open source software platform is revolutionizing digital pathology image analysis

We are delighted to welcome Research Scientist,  Dr. Peter Bankhead to our expert panel of speakers for Pathology Horizons 2018.

Innovation increasingly relies on open tools, standards and software, empowering researchers to test new ideas and make new discoveries.  Reproducibility and standardization in science also crucially depend upon analysis methods being made freely available.

Until recently, digital pathology suffered from the lack of a software platform that would make these things possible.  Faced with a choice between attempting to analyze whole slide images using commercial systems (often prohibitively expensive) or by applying generic open source software (often prohibitively complex), much biomarker analysis in practice continued to be based on visual estimation by pathologists, which is laborious and known to have limited reproducibility.

QuPath was developed to address these issues, and represents the first widely-used, powerful, flexible, extensible and user-friendly open source platform for whole slide image analysis.  Since its release at the end of 2016, QuPath has been downloaded more than 10 000 times and is used worldwide by research groups in both academia and industry.

A central goal of QuPath is to provide the tools for pathologists and image analysts to better work together, advancing the field more rapidly.

During  his presentation at Pathology Horizons, Dr. Bankhead will outline some of the reasons behind QuPath’s success so far, and describe features currently in development that are set to greatly expand its scope and reach for digital pathology and bioimage analysis applications in the near future.

Why attend Pathology Horizons?

The conference is set to be another interesting and extremely informative event with a range of top international speakers demonstrating the power of new technologies, updates on procedural developments and valuable new lines of research – all in a relaxed and open atmosphere! Unlike other larger pathology events, Pathology Horizons is a boutique conference with one conference stream, which allows you to interact and network fully with the delegates and speakers. The conference is also CPD certified and has been awarded with 9 CPD credits by The Royal College of Pathologists.

Some other topics from speakers include: 

  • Artificial intelligence and what it means for healthcare and patholgy
  • Liquid biopsy and what it can do for detecting/treating ovarian cancer
  • Virtual and augmented reality in digital pathology
  • Genome sequencing as a diagnostic aid

View  full Agenda.

Don’t miss out, secure your place today!

Pathology Horizons 2018                                                                                    Lough Erne Resort, N. Ireland                                                                                        13-15th September

Radiology and Pathology Integration – Opportunities Outweigh the Challenges

In recent years, advances in the field of diagnostic medicine have provided enormous benefits to patients with cancer.  However, the increase in complexity of new testing modalities in pathology and radiology has also led to new challenges in gathering all essential information and forming a coherent diagnostic message for a given case.

Opportunities for optimal patient care may be lost, and diagnostic errors might not be prevented, without a formal integration of the various testing modalities in pathology and radiology.  During his presentation at Pathology Horizons 2018, Dr. Wallace will discuss the challenges of pathology and radiology correlation in the current diagnostic paradigm and the numerous opportunities for improved workflows and patient outcomes with an effective diagnostic integration process.

Dr. W. Dean Wallace  is a Professor of Pathology at the UCLA David Geffen School of Medicine in Los Angeles, California. He is the chief of pulmonary and renal pathology services and is recognised as an expert in the fields of transplant pathology and lung cancer diagnostics. Dr. Wallace is also the Director of the UCLA Telepathology and Digital Pathology Centre and co-led the team that created the innovative, first of its kind, Integrated Diagnostic Report (IDR) that combines multiple radiology and pathology studies into one dynamic reporting platform. Dr. Wallace has authored several dozen peer-reviewed papers and book chapters and was lead editor of a textbook in the field of transplant pathology.

Why attend Pathology Horizons?

The conference is set to be another interesting and  informative event with a range of top international speakers demonstrating the power of new technologies, updates on procedural developments and valuable new lines of research – all in a relaxed and open atmosphere! Unlike other larger pathology events, Pathology Horizons is a boutique conference with one conference stream, which allows you to interact and network fully with the delegates and speakers. The conference is also CPD certified and has been awarded with 9 CPD credits by The Royal College of Pathologists.

Some other topics from speakers include: 

  • Artificial intelligence and what it means for healthcare and patholgy
  • Liquid biopsy and what it can do for detecting/treating ovarian cancer
  • Virtual and augmented reality in digital pathology
  • Genome sequencing as a diagnostic aid

Please note places for the conference are limited. If you are planning on attending, booking soon is advisable.  Register here

Pathology Horizons 2018                                                                                    Lough Erne Resort, N. Ireland                                                                                        13-15th September

Development of genomic assays for multi-arm clinical trials in cancer

There are an increasing number of molecular assays being developed to guide patient treatments. There is , however, often a limited amount of material available for analysis. Almac Diagnostics have therefore developed DNA and mRNA next generation sequencing based panels that have been analytically validated to deliver multiple Biomarkers from small amounts of material. An associated comprehensive patient report has been developed to guide the best treatment in oncology trials and eventually in standard clinical practice.

During his presentation at Pathology Horizons 2018 Prof. Kennedy will discuss the challenges to implementing these kind of Biomarker panels in clinical care and how these are being overcome.

Prof. Richard Kennedy is the Medical Director and Global VP of Biomarker Development at Almac Diagnostics and the McClay Professor in Medical Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University of Belfast.

Why attend Pathology Horizons?

The conference is set to be another interesting and extremely informative event with a range of top international speakers demonstrating the power of new technologies, updates on procedural developments and valuable new lines of research – all in a relaxed and open atmosphere! Unlike other larger pathology events, Pathology Horizons is a boutique conference with one conference stream, which allows you to interact and network fully with the delegates and speakers. The conference is also CPD certified and has been awarded with 9 CPD credits by The Royal College of Pathologists.

Other topics from speakers include: 

  • Artificial intelligence and what it means for healthcare
  • Liquid biopsy and what it can do for detecting/treating ovarian cancer
  • Virtual and augmented reality in digital pathology
  • Radiology and pathology integration
  • Genome sequencing as a diagnostic aid

Don’t miss out, secure your place today!

Pathology Horizons 2018                                                                                    Lough Erne Resort, N. Ireland                                                                                        13-15th September

Prof. Levenson to give MUSE update at Pathology Horizons

MUSE (Microscopy with UV Surface Excitation), a novel, fast, simple Microscopy Method for slide-free histology continues to attract interest across the world. In fact, it made the front cover of BioPhotonics Magazine this month. Cirdan first brought Prof. Richard Levenson in to speak on this topic at Pathology Horizons in 2016. We are delighted to confirm that Prof. Levenson will be sharing the latest developments in MUSE at the upcoming Pathology Horizons conference in September.

Digital imaging of tissue slides is part of the future of anatomic pathology. However, as currently implemented, while facilitating logistics and enabling advanced analytical tools, it still requires the preparation of glass slides prior to scanning. An alternative strategy that bypasses conventional histological processing and its associated delays and expense would be useful, and a number of technologies for rapid, ex-vivo, slide-free microscopy are in research-and-development phase and a few have already been deployed as research-use-only commercial instruments. These contenders to replace FFPE-based histology appear promising for such uses as real-time surgical guidance, margin assessment, rapid on-site evaluation (ROSE), and potentially even for final tissue diagnosis, while accelerating care and decreasing costs. 

Prof. Levenson’s presentation entitled: “MUSE for Slide-Free, Real-Time Histology – It’s Cooler than Frozens.” will focus on MUSE and also look at a  few of these methods, including multiphoton and confocal microscopy, light-sheet microscopy, optical coherence tomography and structured illumination.

View. Prof. Levson’s bio

View Pathology Horizons 2018 Agenda

Register here for Early Bird

Dr. Kaplan talks Artificial Intelliegnce: What it Means for Healthcare and Pathology

Recent advances in Artificial Intelligence (AI) show great promise in several fields of medicine.  The field of deep learning is enabling the development of expert-level automated algorithms.

There are two aspects to consider when looking at the value in  using AI. First is the practical aspect. Use of AI can speed up the diagnostic process, ensuring diagnostic assessments are more reproducible. This helps physician productivity by automating some of the decision-making process.

The deeper aspect of AI’s impact is in its ability to analyze the data found. AI algorithms will begin to find patterns a human wouldn’t necessarily see, extending the capability of what physicians can do today. These advances could address the impact treatment of the disease has on outcomes.

AI is simply a tool – not a replacement for a pathologist. Deep learning can be applied to numerous diagnostic tasks and defines a new era in digital pathology.

Dr. Keith Kaplan, Chicago native and Publisher of leading industry blog tissuepathology.com will be discussing artificial intelligence, what it means for healthcare and pathology at the Pathology Horizons Conference this September in N.Ireland.

During his session  Dr. Kaplan will focus on advancements in AI in surgical pathology and what the use of this technology means for the future practice of pathology.

Objectives for this session:

  • Understand basic definitions in AI and deep learning.
  • Review applications and use cases to date within medicine and pathology
  • Discuss implications of AI for the practice of pathology
  • Highlight potential opportunities and weaknesses for AI within pathology

View Conference Agenda

Register now for Early Bird!

UCLA’s Dr. Wallace to speak on radiology and pathology integration at Pathology Horizons 2018

We are delighted to have Dr. Dean. W. Wallace, Professor of Pathology at the UCLA David Geffen School of Medicine in Los Angeles speak at Pathology Horizons 2018.

His talk at the conference ‘Opportunities Outweigh the Challenges of Radiology and Pathology Integration’ is an emerging area of discussion, and if implemented could help improve the overall quality of patient care. An abstract of Dr. Wallace’s talk will be released in the coming weeks and you will have the opportunity to hear his full presentation in September at the Lough Erne Resort in Northern Ireland.

More information on Dr. Wallace

Dr. Wallace is the chief of pulmonary and renal pathology services and is recognised as an expert in the fields of transplant pathology and lung cancer diagnostics. He is also the Director of the UCLA Telepathology and Digital Pathology Centre and co-led the team that created the innovative, first of its kind, Integrated Diagnostic Report (IDR) that combines multiple radiology and pathology studies into one dynamic reporting platform. Dr. Wallace has authored several dozen peer-reviewed papers and book chapters and was lead editor of a textbook in the field of transplant pathology.

About Pathology Horizons

 Pathology Horizons is an annual and open CPD conference organised by Cirdan to discuss what developments lie ahead in Pathology and what we can do to prepare or take advantage of these. Delegates will learn about new technologies, procedural developments and lines of research that are driving the future of pathology.

View conference agenda.

Places are limited, so please register early to avoid disappointment. Register for early bird now!

 

Hear from Dr. Buckley on the “Application of Liquid Biopsy to the Detection and Treatment of Ovarian Cancer”

We are delighted to welcome Dr. Niamh Buckley of Queen’s University Belfast to our panel of speakers for this year’s Pathology Horizons Conference in N. Ireland.

Dr. Buckley’s presentation, entitled: “Application of Liquid Biopsy to the Detection and Treatment of Ovarian Cancer” will focus on a project that she is currently working on.

About Dr. Buckley

Dr Niamh Buckley graduated from Trinity College, Dublin in 2002 with a First Class Honours Degree in Biochemistry.  She then carried out her Ph.D training in the Department of Oncology (Queen’s University Belfast) under the supervision of Prof. Paul Harkin.  Following this, she then worked as a post-doctoral researcher with Dr Paul Mullan in the Centre for Cancer Research and Cell Biology (Queen’s University Belfast).  During this time she investigated the role of the breast and ovarian tumour suppressor gene, BRCA1, in stem cell regulation and mammary gland differentiation.

Dr Buckley was awarded the prestigious Breast Cancer Now Fellowship in 2013 to develop novel biomarkers and therapeutic strategies in BRCA1-mutant and/or triple negative breast cancer.  In 2016 she was appointed as a Lecturer in Personalised Medicine and Pharmacogenomics in the School of Pharmacy (Queen’s University Belfast).  Her research focuses on the integration of in vitro, in vivo, bioinformatics and pathology approaches to identify key pathways underpinning poor outcome breast cancer and use detailed knowledge of this biology to identify appropriate targeted treatment options, personalising therapy in an area of unmet clinical need.

About Pathology Horizons

Pathology Horizons is an annual CPD conference focused on the future of pathology. Delegates will learn about new technologies, procedures and lines of research that are driving the future of pathology. This year the conference is being held in the five star Lough Erne Resort, Co. Fermanagh in N.Ireland from 13-15 September 2018.

View conference speakers and find out more  on how to register.

Early Bird Tickets now available.

Pathology Horizons is coming to N.Ireland

September 2018 will see Cirdan host the next Pathology Horizons conference in Northern Ireland for the first time ever.  Previous event locations have included Cairns and Fraser Island, Australia and Galway, Ireland. Pathology Horizons 2018 will be the fourth conference run by Cirdan and is to be held in the superb, five star Lough Erne Resort in County Fermanagh from 13 – 15 September.

Overview

Pathology Horizons is an annual CPD conference focused on the future of pathology and looking at what lies ahead in this area. The conference will attract expert speakers and delegates from all over the world.

Why attend?

This unique event will give delegates the chance to learn about new technologies, procedural developments and lines of research that are driving the future of pathology. They will hear about the pros and cons of these developments, how people in supporting disciplines should be preparing for and perhaps directing these changes and their potential impact on the daily work of a Pathologist.

Unlike many other events, Pathology Horizons is a boutique conference that provides an opportunity for delegates to contribute their ideas and interact with innovators from around the world, while expanding their knowledge and making some new contacts.

Who should attend?

The Pathology Horizons 2018 conference is open to anyone who is interested in the area of pathology e.g. Pathologists, Laboratory Managers and Biomedical Scientist.

Pathology Horizons 2017 Overview

The overview video of Pathology Horizons 2017 in Cairns will provide some insight into the conference content and give you a good feel for the event.

Get notified when Pathology Horizons 2018 conference registration opens.